Search

Your search keyword '"Amado, Rafael"' showing total 187 results
Start Over Author "Amado, Rafael"
187 results on '"Amado, Rafael"'

1. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells

Author

Sasu, Barbra J., Opiteck, Gregory J., Gopalakrishnan, Suhasni, Kaimal, Vivek, Furmanak, Tom, Huang, David, Goswami, Angshumala, He, Ying, Chen, Jiamin, Nguyen, Anh, Balakumaran, Arun, Shah, Nirav N., Hamadani, Mehdi, Bone, Kathleen M., Prashad, Sacha, Bowen, Michael A., Pertel, Thomas, Embree, Heather D., Gidwani, Shalini G., Chang, David, Moore, Alison, Leonard, Mark, and Amado, Rafael G.

Published
2023
Full Text
View/download PDF

2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Author

Ramachandran, Indu, Lowther, Daniel E, Dryer-Minnerly, Rebecca, Wang, Ruoxi, Fayngerts, Svetlana, Nunez, Daniel, Betts, Gareth, Bath, Natalie, Tipping, Alex J, Melchiori, Luca, Navenot, Jean-Marc, Glod, John, Mackall, Crystal L, D’Angelo, Sandra P, Araujo, Dejka M, Chow, Warren A, Demetri, George D, Druta, Mihaela, Van Tine, Brian A, Grupp, Stephan A, Abdul Razak, Albiruni R, Wilky, Breelyn, Iyengar, Malini, Trivedi, Trupti, Winkle, Erin Van, Chagin, Karen, Amado, Rafael, Binder, Gwendolyn K, and Basu, Samik

Subjects
Vaccine Related, Biotechnology, Immunization, Cancer, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Antigens, Neoplasm, Biomarkers, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Cytokines, Cytotoxicity, Immunologic, HLA-A Antigens, Humans, Immunohistochemistry, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating, Membrane Proteins, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Sarcoma, Synovial, T-Cell Antigen Receptor Specificity, T-Lymphocytes, Treatment Outcome, Tumor Microenvironment, Adoptive immunotherapy, Synovial sarcoma, NY-ESO-1, Fludarabine, Cyclophosphamide, T cell, TCR, IL-15, Cytokine, Antigen loss, Checkpoint therapy, Engineered cell therapy
Abstract

BackgroundGene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma (SS). The factors contributing to gene-modified T-cell expansion and the changes within the tumor microenvironment (TME) following T-cell infusion remain unclear. These studies address the immunological mechanisms of response and resistance in patients with SS treated with NY-ESO-1 SPEAR T-cells.MethodsFour cohorts were included to evaluate antigen expression and preconditioning on efficacy. Clinical responses were assessed by RECIST v1.1. Engineered T-cell persistence was determined by qPCR. Serum cytokines were evaluated by immunoassay. Transcriptomic analyses and immunohistochemistry were performed on tumor biopsies from patients before and after T-cell infusion. Gene-modified T-cells were detected within the TME via an RNAish assay.ResultsResponses across cohorts were affected by preconditioning and intra-tumoral NY-ESO-1 expression. Of the 42 patients reported (data cut-off 4June2018), 1 patient had a complete response, 14 patients had partial responses, 24 patients had stable disease, and 3 patients had progressive disease. The magnitude of gene-modified T-cell expansion shortly after infusion was associated with response in patients with high intra-tumoral NY-ESO-1 expression. Patients receiving a fludarabine-containing conditioning regimen experienced increases in serum IL-7 and IL-15. Prior to infusion, the TME exhibited minimal leukocyte infiltration; CD163+ tumor-associated macrophages (TAMs) were the dominant population. Modest increases in intra-tumoral leukocytes (≤5%) were observed in a subset of subjects at approximately 8 weeks. Beyond 8 weeks post infusion, the TME was minimally infiltrated with a TAM-dominant leukocyte infiltrate. Tumor-associated antigens and antigen presentation did not significantly change within the tumor post-T-cell infusion. Finally, NY-ESO-1 SPEAR T cells trafficked to the TME and maintained cytotoxicity in a subset of patients.ConclusionsOur studies elucidate some factors that underpin response and resistance to NY-ESO-1 SPEAR T-cell therapy. From these data, we conclude that a lymphodepletion regimen containing high doses of fludarabine and cyclophosphamide is necessary for SPEAR T-cell persistence and efficacy. Furthermore, these data demonstrate that non-T-cell inflamed tumors, which are resistant to PD-1/PD-L1 inhibitors, can be treated with adoptive T-cell based immunotherapy.Trial registrationClinicalTrials.gov, NCT01343043 , Registered 27 April 2011.

Published
2019

5. List of Contributors

Author

Allickson, Julie G., primary, Amado, Rafael G., additional, Azam, Usman, additional, Barry, Frank, additional, Bilbao, Irene Aldecoa, additional, Binder, Gwendolyn K., additional, Black, Justin L., additional, Blumer, Karin, additional, Brandon, Eugene P., additional, Brindley, David A., additional, Burns, William Murray, additional, Capone, Francesca, additional, Carmona, Guillaume, additional, Chaffman, Michael, additional, Chou, William, additional, Cui, Zhanfeng, additional, D’Amour, Kevin A., additional, Dowden, Nathan J., additional, Eschgfaeller, Bernd, additional, Faulkner, Eric, additional, Galli, Maria Cristina, additional, Goshima, Yoshio, additional, Haggarty, Stephen J., additional, Halioua-Haubold, Celine-Lea, additional, Harrington-Smith, Kristen, additional, Hickerson, Darren, additional, Ho, William, additional, Hyllner, Johan, additional, Iyer, Natasha, additional, Jansen, Marieke, additional, Jousseaume, Etienne, additional, Kili, Sven, additional, Konski, Antoinette F., additional, Lamb, Lawrence S., additional, Lam, Ching, additional, Lim, Jaeseung, additional, Lo, Chi, additional, Malcolm, Thomas, additional, Martinez-Fernandez, Almudena, additional, Meinecke, Todd, additional, Meinert, Edward, additional, Milone, Michael C., additional, Mitchell, David A., additional, Muni, Niraj, additional, Nappi, Filomena, additional, Nathan, Neal H., additional, Ostuni, Emanuele, additional, Papakosta, Marianthi, additional, Paratore, Simona, additional, Pascali, Vincenzo Lorenzo, additional, Pernia, Cameron D., additional, Philipson, Benjamin, additional, Phillips, Fiona, additional, Phillips, James B., additional, Qureshi, Nasib, additional, Refolo, Pietro, additional, Ringo, Moira, additional, Robson, Matthew, additional, Ruff, Crystal, additional, Schmidt, Manuel, additional, Schroff, Matthias, additional, Scott, Michael J., additional, Sharpe, Michaela, additional, Sidman, Richard L., additional, Sinden, John D., additional, Smith, Devyn M., additional, Snyder, Evan Y., additional, Somara, Sita, additional, Spagnolo, Antonio Gioacchino, additional, Spinner, Daryl S., additional, Sridharan, Kanaka, additional, Sullivan, Michael, additional, Thompson, Keith, additional, Tobe, Brian T.D., additional, Vertès, Alain A., additional, West, Michael D., additional, Wilkins-Port, Cynthia, additional, Wittig, Burghardt, additional, Yang, Aidong, additional, Zhang, Jie, additional, and Zimmerman, Mark C., additional

Published
2020
Full Text
View/download PDF

6. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

Author

Britten, Carolyn D, Gomes, Antoinette S, Wainberg, Zev A, Elashoff, David, Amado, Rafael, Xin, Yan, Busuttil, Ronald W, Slamon, Dennis J, and Finn, Richard S

Abstract

Abstract Background Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE. Methods 30 subjects with HCC undergoing TACE at a single academic institution were randomized with a computer-generated allocation in a one to one ratio to either bevacizumab at a dose of 10 mg/kg IV every 14 days beginning 1 week prior to TACE (TACE-BEV arm) or observation (TACE-O arm). Angiography was performed with TACE at day 8, and again at weeks 10 and 14. Repeat TACE was performed at week 14 if indicated. TACE-BEV subjects were allowed to continue bevacizumab beyond week 16. TACE-O subjects were allowed to cross-over to bevacizumab at week 16 in the setting of progressive disease. The main outcome measure was a comparison of neovessel formation by serial angiography. Secondary outcome measures were progression free survival (PFS) at 16 weeks, overall survival (OS), bevacizumab safety, and an analysis of VEGF levels before and after TACE with and without bevacizumab. Results Among the 30 subjects enrolled, 9 of 15 randomized to the TACE-O arm and 14 of 15 randomized to the TACE-BEV arm completed all 3 angiograms. At week 14, 3 of 9 (33%) TACE-O subjects and 2 of 14 (14%) TACE-BEV subjects demonstrated neovascularity. The PFS at 16 weeks was 0.19 in the TACE-O arm and 0.79 in the TACE-BEV arm (p = 0.021). The median OS was 61 months in the TACE-O arm and 49 months in the TACE-BEV arm (p = 0.21). No life-threatening bevacizumab-related toxicities were observed. There were no substantial differences in bevacizumab pharmacokinetics compared to historical controls. Bevacizumab attenuated the increase in VEGF observed post-TACE. Conclusions IV bevacizumab was well tolerated in selected HCC subjects undergoing TACE, and appeared to diminish neovessel formation at week 14. Trial registration ClinicalTrials.gov NCT00049322.

Published
2012

9. Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

Author

D'Angelo, Sandra P., primary, Melchiori, Luca, primary, Merchant, Melinda S., primary, Bernstein, Donna, primary, Glod, John, primary, Kaplan, Rosandra, primary, Grupp, Stephan, primary, Tap, William D., primary, Chagin, Karen, primary, Binder, Gwendolyn K., primary, Basu, Samik, primary, Lowther, Daniel E., primary, Wang, Ruoxi, primary, Bath, Natalie, primary, Tipping, Alex, primary, Betts, Gareth, primary, Ramachandran, Indu, primary, Navenot, Jean-Marc, primary, Zhang, Hua, primary, Wells, Daniel K., primary, Van Winkle, Erin, primary, Kari, Gabor, primary, Trivedi, Trupti, primary, Holdich, Tom, primary, Pandite, Lini, primary, Amado, Rafael, primary, and Mackall, Crystal L., primary

Published
2023
Full Text
View/download PDF

10. Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

Author

D'Angelo, Sandra P., primary, Melchiori, Luca, primary, Merchant, Melinda S., primary, Bernstein, Donna, primary, Glod, John, primary, Kaplan, Rosandra, primary, Grupp, Stephan, primary, Tap, William D., primary, Chagin, Karen, primary, Binder, Gwendolyn K., primary, Basu, Samik, primary, Lowther, Daniel E., primary, Wang, Ruoxi, primary, Bath, Natalie, primary, Tipping, Alex, primary, Betts, Gareth, primary, Ramachandran, Indu, primary, Navenot, Jean-Marc, primary, Zhang, Hua, primary, Wells, Daniel K., primary, Van Winkle, Erin, primary, Kari, Gabor, primary, Trivedi, Trupti, primary, Holdich, Tom, primary, Pandite, Lini, primary, Amado, Rafael, primary, and Mackall, Crystal L., primary

Published
2023
Full Text
View/download PDF

13. Latent human herpesvirus 6 is reactivated in chimeric antigen receptor T cells

Author

Lareau, Caleb A., primary, Yin, Yajie, additional, Maurer, Katie, additional, Sandor, Katalin D., additional, Yagnik, Garima, additional, Peña, José, additional, Crawford, Jeremy Chase, additional, Spanjaart, Anne M., additional, Gutierrez, Jacob C., additional, Haradhvala, Nicholas J., additional, Abay, Tsion, additional, Stickels, Robert R., additional, Verboon, Jeffrey M., additional, Liu, Vincent, additional, Southard, Jackson, additional, Song, Ren, additional, Li, Wenjing, additional, Shrestha, Aastha, additional, Parida, Laxmi, additional, Getz, Gad, additional, Maus, Marcela V., additional, Li, Shuqiang, additional, Moore, Alison, additional, Amado, Rafael G., additional, Talleur, Aimee C., additional, Thomas, Paul G., additional, Dehghani, Houman, additional, Pertel, Thomas, additional, Kundaje, Anshul, additional, Gottschalk, Stephen, additional, Roth, Theodore L., additional, Kersten, Marie J., additional, Wu, Catherine J., additional, Majzner, Robbie G., additional, and Satpathy, Ansuman T., additional

Published
2022
Full Text
View/download PDF

21. Comprehensive study of 3D chromatin structure

Author

Lema Amado, Rafael, Orozco López, Modesto, Universitat de Barcelona. Facultat de Biologia, and Brun-Heath, Isabelle

Subjects
Cromatina, Estrès oxidatiu, Oxidative stress, ADN, Estrés oxidativo, Nuclis cel·lulars, DNA, Núcleos celulares, Cell nuclei, Ciències Experimentals i Matemàtiques, Chromatin
Abstract

The connection between DNA folding and chromatin conformation has been much studied but the relation between the modulation of chromatin conformation and biological processes such as DNA damage, cell differentiation and DNA replication, still remains unclear. To better understand these mechanisms, an interdisciplinary study combining several technologies is required to provide an integrative view of what happens from the level of nucleosome interactions up to whole genome organisation. In this thesis, we aimed to set up chromatin conformation methodologies such as Hi-C and Micro-C to analyse the effect of DNA damage and cell differentiation on 3D chromatin structure. Chromatin structure is affected by DNA damage caused by UV irradiation or oxidative stress. In our study, the effects of UV irradiation and oxidative stress on 3D genome structure were analysed from nucleosome positioning to chromatin conformation. Molecular Dynamics simulation and Coarse grained modelling provided a 3D model of the whole genome of Saccharomyces cerevisiae in normal and stressed conditions. The conditions of UV irradiation that was applied created a decrease of chromatin interactions increasing chromatin flexibility. In addition, oxidative stress induced chromatin changes with an increase of inter-chromosomal interactions and a reduction of intra-chromosomal interactions. These effects were associated with a decrease in the number of chromatin interaction domains (CID) as well as the insulation score. The reduction of CID is correlated with a reduction of cohesin loading factor complex (SCC2/SCC4) bound to the chromatin upon oxidative stress. In addition, nucleosome contacts were globally reduced, especially in upregulated genes and DNA damaged regions. Concerning nucleosome positioning, a general increase of the fuzziness score was observed both in upregulated and downregulated genes, and in regions of DNA damage in response to oxidative stress. Overall, our results showed a decrease in the number of nucleosomes and a tendency of the chromatin to be more open at short-range distances while, at long-range distances, the genome seems to be more compact in response to oxidative stress. One hypothesis could be that chromatin decondensation can contribute to facilitate DNA repair. MD simulations were used to build two models: one at the scale of the chromatin fibre and the other one for the whole genome. Finally, high resolution microscopy combined with Capture-MNase-Seq, Capture-Hi-C and coarse grain models were used to study the conformational changes occurring during cell reprograming from fibroblast to hiPSC. A specific region containing NANOG and STELLA loci as well as GADPH and IFFO1 as control genes was selected. Capture- MNase-Seq and Capture-Hi-C revealed that nucleosomes tend to be fuzzier in the pluripotent hiPSC cells and that the TADs were reorganized during cell differentiation.

Published
2020

27. MOESM3 of Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Author

Ramachandran, Indu, Lowther, Daniel, Dryer-Minnerly, Rebecca, Ruoxi Wang, Fayngerts, Svetlana, Nunez, Daniel, Betts, Gareth, Bath, Natalie, Tipping, Alex, Melchiori, Luca, Jean-Marc Navenot, Glod, John, Mackall, Crystal, D’Angelo, Sandra, Dejka Araujo, Chow, Warren, Demetri, George, Druta, Mihaela, Tine, Brian, Grupp, Stephan, Albiruni Abdul Razak, Breelyn Wilky, Iyengar, Malini, Trupti Trivedi, Winkle, Erin, Chagin, Karen, Amado, Rafael, Binder, Gwendolyn, and Samik Basu

Subjects
sense organs
Abstract

Additional file 3: Figure S2. Change in antigen expression at progression. NY-ESO-1 protein expression H-scores as determined by IHC in pre-infusion and post-progression biopsies from all patients whose progression biopsies were evaluable (NÂ =â 15). Paired Mann-Whitney U statistical test was used to evaluate changes between pre-infusion and progression time points.

Published
2019
Full Text
View/download PDF

33. Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma

Author

Goyal, Lipika, primary, Frigault, Matthew, additional, Meyer, Tim, additional, Feun, Lynn G., additional, Bruix, Jordi, additional, El-Khoueiry, Anthony, additional, Hausner, Petr, additional, Sangro, Bruno, additional, Pierce, Theodore T., additional, Norry, Elliot, additional, Ranganathan, Sulabha, additional, Amado, Rafael G., additional, and Finn, Richard S., additional

Published
2019
Full Text
View/download PDF

34. Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma

Author

D'Angelo, Sandra P., primary, Araujo, Dejka, additional, Tine, Brian Van, additional, Demetri, George, additional, Dutra, Mihaela, additional, Glod, John, additional, Chow, Warren, additional, Grupp, Stephen, additional, Razak, Alibiruni Abdul, additional, Tap, William, additional, Wilky, Breelyn, additional, Winkle, Erin Van, additional, Norry, Elliott, additional, Basu, Samik, additional, Chagin, Karen, additional, Iyengar, Malini, additional, Trivedi, Trupti, additional, Amado, Rafael, additional, and Mackall, Crystal, additional

Published
2019
Full Text
View/download PDF

35. Abstract A002: Autologous Tcells transduced with the affinity enhanced NY-ESO-1c259TCR in patients with synovial sarcoma expressing low levels of the NY-ESO-1 antigen

Author

Araujo, Dejka, primary, D'Angelo, Sandra, additional, Demetri, George, additional, Druta, Mihaela, additional, Glod, John, additional, Chow, Warren, additional, Tap, William, additional, Senra, Joana, additional, Abbott, Rachel, additional, Winkle, Erin Van, additional, Chagin, Karen, additional, Maroto, Miguel, additional, Norry, Elliot, additional, Iyengar, Malini, additional, Trivedi, Trupti, additional, Gerry, Andrew, additional, Amado, Rafael, additional, and Mackall, Crystal, additional

Published
2019
Full Text
View/download PDF

36. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

Author

D'Angelo, Sandra P., primary, Melchiori, Luca, additional, Merchant, Melinda S., additional, Bernstein, Donna, additional, Glod, John, additional, Kaplan, Rosandra, additional, Grupp, Stephan, additional, Tap, William D., additional, Chagin, Karen, additional, Binder, Gwendolyn K., additional, Basu, Samik, additional, Lowther, Daniel E., additional, Wang, Ruoxi, additional, Bath, Natalie, additional, Tipping, Alex, additional, Betts, Gareth, additional, Ramachandran, Indu, additional, Navenot, Jean-Marc, additional, Zhang, Hua, additional, Wells, Daniel K., additional, Van Winkle, Erin, additional, Kari, Gabor, additional, Trivedi, Trupti, additional, Holdich, Tom, additional, Pandite, Lini, additional, Amado, Rafael, additional, and Mackall, Crystal L., additional

Published
2018
Full Text
View/download PDF

37. Abstract 2562: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4

Author

Senra, Joana, primary, Villalobos, Pamela, additional, Mino, Barbara, additional, Solis, Luisa, additional, Behrens, Carmen, additional, Sanderson, Joseph P., additional, Saini, Manoj, additional, Gerry, Andrew B., additional, Pumphrey, Nicholas J., additional, Maroto, Miguel, additional, Sepesi, Boris, additional, Hwu, Patrick, additional, Hong, David S., additional, Mittendorf, Elizabeht A., additional, Blumenschein, George S., additional, Wistuba, Ignacio I., additional, Binder-Scholl, Gwendolyn, additional, and Amado, Rafael, additional

Published
2018
Full Text
View/download PDF

39. Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

Author

Lam, Vincent K., primary, Hong, David S., additional, Heymach, John, additional, Blumenschein, George R., additional, Creelan, Ben C., additional, Bradbury, Penelope Ann, additional, Butler, Marcus O., additional, Gainor, Justin F., additional, Govindan, Ramaswamy, additional, Johnson, Melissa Lynne, additional, Mudad, Raja, additional, Sullivan, Ryan J., additional, Brophy, Francine, additional, Hyland, Natalie, additional, Chagin, Karen, additional, Holdich, Tom, additional, Norry, Elliot, additional, and Amado, Rafael G., additional

Published
2018
Full Text
View/download PDF

41. Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

Author

Rapoport, Aaron P., primary, Stadtmauer, Edward A, additional, Chagin, Karen, additional, Faitg, Thomas, additional, Iyengar, Malini, additional, Trivedi, Trupti, additional, Norry, Elliot, additional, Holdich, Tom, additional, Binder-Scholl, Gwendolyn, additional, Amado, Rafael, additional, and Fang, Frank, additional

Published
2017
Full Text
View/download PDF

42. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

Author

Odunsi, Kunle, primary, Cristea, Mihaela C., additional, Dorigo, Oliver, additional, Jazaeri, Amir A., additional, Slomovitz, Brian M., additional, Chagin, Karen, additional, Van Winkle, Erin, additional, Kari, Gabor, additional, Iyengar, Malini, additional, Norry, Elliot, additional, Bartlett-Pandite, Arundathy N., additional, and Amado, Rafael G., additional

Published
2017
Full Text
View/download PDF

43. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).

Author

D'Angelo, Sandra P., primary, Druta, Mihaela, additional, Demetri, George D., additional, Liebner, David A., additional, Schuetze, Scott, additional, Singh, Arun S., additional, Somaiah, Neeta, additional, Van Tine, Brian Andrew, additional, Wilky, Breelyn A., additional, Chagin, Karen, additional, Pulham, Tim, additional, Iyengar, Malini, additional, Norry, Elliot, additional, Bartlett-Pandite, Arundathy N., additional, and Amado, Rafael G., additional

Published
2017
Full Text
View/download PDF

44. Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).

Author

Creelan, Ben C., primary, Gainor, Justin F., additional, Govindan, Ramaswamy, additional, Hardy, Nancy M., additional, Heymach, John, additional, Mudad, Raja, additional, Reckamp, Karen L., additional, Bardwell, William, additional, Holdich, Tom, additional, Bartlett-Pandite, Arundathy N., additional, and Amado, Rafael G., additional

Published
2017
Full Text
View/download PDF

45. Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Author

Mackall, Crystal, primary, Tap, William D., additional, Glod, John, additional, Druta, Mihaela, additional, Chow, Warren Allen, additional, Araujo, Dejka M., additional, Grupp, Stephan A., additional, Van Tine, Brian Andrew, additional, Chagin, Karen, additional, Van Winkle, Erin, additional, Kari, Gabor, additional, Trivedi, Trupti, additional, Norry, Elliot, additional, Holdich, Tom, additional, Bartlett-Pandite, Arundathy N., additional, Amado, Rafael G., additional, and D'Angelo, Sandra P., additional

Published
2017
Full Text
View/download PDF

47. Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Author

Mackall, Crystal, primary, D'Angelo, Sandra P., additional, Grupp, Stephan A., additional, Odunsi, Kunle, additional, Cristea, Mihaela C., additional, Linette, Gerald P., additional, Kluger, Harriet M., additional, Kari, Gabor, additional, Pandite, Lini, additional, Holdich, Tom, additional, Norry, Elliot, additional, Binder-Scholl, Gwendolyn, additional, and Amado, Rafael G., additional

Published
2016
Full Text
View/download PDF

49. Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

Author

Mackall, Crystal, primary, D'Angelo, Sandra P., additional, Cristea, Mihaela C., additional, Odunsi, Kunle, additional, Norry, Elliot, additional, Pandite, Lini, additional, Holdich, Tom, additional, Kari, Gabor, additional, Ramachandran, Indu R., additional, Ribeiro, Lilliam, additional, Binder-Scholl, Gwendolyn, additional, and Amado, Rafael G., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results